Retinal anti-VEGF regimens requiring frequent monitoring generate indirect patient costs that often outweigh direct expenses ...
In two studies in retinal disease, faricimab shows improved vision and a reduced injection burden in people who switched from ...
MedPage Today on MSN
Anti-VEGF agent collects big win in trial of diabetic retinopathy
More than 60% of tarcocimab-treated patients had reduced severity ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ...
How anti-VEGF injections reshape wet AMD, DME, and vein occlusion care, preserving vision—plus what real-world access barriers mean for patients. Welcome back to another AJMC Insights series. In this ...
MedPage Today on MSN
Vision benefits in GA with complement inhibitor, regardless of AMD, anti-VEGF
Largest effects seen in eyes with GA and AMD, dual treatment with pegcetacoplan, VEGF inhi ...
At the 131st Congress of the French Society of Ophthalmology in Paris, France, the role of second-generation intravitreal anti-VEGF injections compared to corticosteroid injections in treating ...
Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...
Vascular endothelial growth factor (VEGF) is pivotal for blood vessel formation and haematopoiesis, but its effect on stem cells has remained unclear. In 27 June Nature, Hans-Peter Gerber and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results